Malignant Liver Lesions on MRI
Content Reviewed: December 26, 2021
2.5 CME
51 Clinical Cases
38 Videos
2 hr. 30 min.
Course Description
After lung cancer, hepatocellular carcinoma has one of the highest mortality rates, making its detection and management critical for all patients. Learning about the vital role MRI plays in diagnosing liver cancer will make you feel more confident in your clinical practice.
In this course, Dr. Mahun Mathur (Yale School of Medicine) examines some of the most common causes of malignant liver lesions in this region. Interpret alongside Dr. Mathur as he walks you through some of the most common diagnoses using annotations, case reviews, and helpful summaries.
Topics covered in this course:
- Liver protocols (localized, T2 weighted image, T1 In-phase and out-of-phase, & T1 pre and post contrast)
- Liver anatomy
- Interpretation of MRI sequences
- LI-RADS scores 1-5
- Morphologic cirrhosis
- Dysplastic nodules
- Treatment options
- …and more!
What your colleagues liked about this series:
- “Incredible lecture series”
- “Great case by case guidance review in short time”
- “I hope even more of the courses I will look at will be like this.”
Check out these other Radiology CME courses:
Dr. Mathur's latest course on Malignant Liver Lesions covers the 6 most common causes of cancer- malignant liver lesions.
Faculty
Mahan Mathur, MD
Associate Professor, Division of Body Imaging; Vice Chair of Education, Dept of Radiology and Biomedical Imaging
Yale School of Medicine
Malignant Liver Lesions Pre-Course Activities
0 / 1
Video
|
5 min.
1 DICOM Case File
Introduction and Anatomy
0 / 2
Videos
|
13 min.
2 DICOM Case Files
Malignant Liver Lesion Case Review
0 / 35
Videos
|
2 hr. 11 min.
49 DICOM Case Files
Morphologic Cirrhosis
5 m
Non-Malignant Nodules in the Cirrhotic Liver
2 m
Dysplastic Nodules
4 m
Portal Hypertension – 2 Patient Case Review
3 m
Pseudocirrhosis
2 m
LI-RADS – Summary
11 m
LI-RADS 1 or 2
2 m
LI-RADS 3
3 m
LI-RADS 3 (THID)
3 m
LI-RADS 4
2 m
LI-RADS 3 Upgraded to LI-RADS 4
4 m
LI-RADS 5
3 m
LI-RADS 5 Change in Lesion Overtime
3 m
LI-RADS 5 – Non-peripheral Washout (NPWO)
3 m
LI-RADS 4 – Psuedo Capsule
3 m
LI-RADS 3 – No Ancillary Imaging Findings
3 m
LI-RADS 5 – Size, Psuedo Capsule, & NPWO
2 m
LI-RADS 5 – 22mm with NPWO
3 m
LI-RADS 4 – Greater than 20mm, Lacking Ancillary Features
3 m
LI-RADS 5 – All-qualifiers, HCC
3 m
LI-RADS – Tumor in Vein (TIV)
5 m
LI-RADS – TIV Infiltrative Tumor
3 m
LI-RADS M – Metastatic Urothelial Cancer
4 m
Fibrolamellar Hepatocellular Carcinoma (FHCC)
6 m
Treatment Options
8 m
Successfully Treated LI-RADS 5
4 m
Successfully treated LI-RADS 5, with Recurrence
4 m
2 Lesions Treated with Transarterial Embolization
4 m
Partially Successful TASE
3 m
Recurrence in a Patient Treated with Radioembolization (Y-90)
3 m
2 Patients with Cholangiocarcinoma
8 m
Hypervascular Mets
4 m
Hypovascular Metastasis from Breast Cancer
3 m
Mucinous Liver Metastasis
3 m
Hypovascular Metastasis Post-op
3 m
Course Evaluation
© 2024 Medality. All Rights Reserved.